Group 1 - The core viewpoint of the article is that Zeling Bio has submitted its listing application to the Hong Kong Stock Exchange, with Jefferies and CICC as joint sponsors [1] - Zeling Bio is a late-stage clinical biotechnology company focused on developing differentiated small molecule therapies to address significant medical needs in hematological diseases and oncology [1] - The company has established a diversified pipeline consisting of eight proprietary assets, which includes two core products, two clinical-stage candidates, and four preclinical-stage candidates as of January 5, 2026 [1] Group 2 - Among the candidates, two have entered Phase 3 registrational clinical trials: Malonic Acid Fluorotidine (FM) for treating myelofibrosis and Puyisitan Sulfate (PM) for treating relapsed/refractory diffuse large B-cell lymphoma [1] - Currently, Zeling Bio has no products approved for commercial sale, with other income and revenue reported as 19.661 million and 7.126 million respectively for the periods ending December 31, 2024, and September 30, 2025 [1]